Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
AlphaTON Capital Corp. Common Stock (ALP)
Road Town, VG
As a technology enterprise, Alpha Compute Corp. focuses on the expansion of the Telegram super application, alongside maintaining a strategic portfolio of digital assets. The company's robust approach to mergers and acquisitions (M&A) and treasury management involves direct procurement of digital assets, engagement in validator operations, and focused investments within the broader digital ecosystem. These initiatives are designed to yield consistent, long-term returns for its shareholders. Founded in 1973 by Gregory H. Bailey and James Mellon, Alpha Compute Corp. is based in Road Town, British Virgin Islands.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-04 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 2 |
4.88
+1,429.8%
|
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-54.6% Q3'25: -3,341.7% (vs Q3'24)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q3'25: -476.2% (vs Q3'24)
-
Share dilution Biotechnology: -3.4%-94.2% ★ Q3'25: -77.7% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q3'25: 0.00× (vs Q3'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
—
|
1.20M
1.20M – 1.20M
|
35.70M
35.70M – 35.70M
+2,875.0% YoY
|
35.70M
35.70M – 35.70M
+0.0% YoY
|
| EBITDA |
-6.74M
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-6.78M
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-6.77M
est: -15.38M (+56.0%)
|
-2.02M
-2.02M – -2.02M
+86.8% YoY
|
-627.0K
-627.0K – -627.0K
+69.0% YoY
|
-627.0K
-627.0K – -627.0K
+0.0% YoY
|
| SGA |
4.25M
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-5.72
est: -13.00 (+56.0%)
|
-1.71
-1.71 – -1.71
+86.8% YoY
|
-0.53
-0.53 – -0.53
+69.0% YoY
|
-0.53
-0.53 – -0.53
+0.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-18 | Villani Fiorenzo | Director / Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 100,831 | I | ↗ |
| 2026-03-18 | Terpin Michael | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Levitt Wesley Allen | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Kaiser Brittany | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Wesley Allen Levitt | Chief Financial Officer | 518.2K | male |
| Robert A. Kramer | Chief Scientific Officer | 119.3K | — |
| Logan Ryan Golema | Chief Technology Officer | — | male |
| Adam Melero | Controller | — | — |
| William De'Ath | Chief Partnership Officer | — | male |
| Peter Molloy | Chief Executive Officer of Cyncado Therapeutics Inc. | — | male |
| Brittany Kaiser | CEO & Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
